Quantcast

Latest Anti-diabetic medication Stories

2014-06-16 16:25:39

Phase 3 Study Results Also Demonstrate INVOKANA® Reduces Secondary Endpoints of Body Weight and Systolic Blood Pressure RARITAN, N.J., June 16, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced new results from a 104-week Phase 3 clinical study evaluating the long-term effects of INVOKANA(®) (canagliflozin) in patients aged 55 to 80 years with type 2 diabetes inadequately controlled on current antihyperglycemic therapies. The randomized double-blind...

2014-06-16 12:58:06

Merck Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA® (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions....

2014-06-15 15:18:02

The Endocrine Society Study suggests metformin controls blood sugar more effectively in African-Americans African Americans taking the diabetes drug metformin saw greater improvements in their blood sugar control than white individuals who were prescribed the same medication, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). An estimated 29 million Americans have diabetes. African Americans are twice as likely to...

2014-06-15 08:21:29

-- The average HbA1C reductions in patients treated with ITCA 650 for 6 months at the time of the interim analysis were -3.2%; patients at baseline had HbA1C levels between 10-12%. BOSTON, June 15, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) held in San Francisco that contained the first 6-month data from an ongoing open-label phase 3 trial...

2014-06-14 12:20:53

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Data from a new phase 3 study demonstrated that once-daily Victoza(R) (liraglutide [rDNA origin] injection) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment.[1],[2] The data were presented today at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, CA. Renal impairment is one of the more...

2014-06-14 12:20:36

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year.[1] Findings from the 26-week extension of the DUAL(TM) I clinical trial programme were presented today at the 74th Annual Scientific Sessions of the American...

2014-06-14 12:20:29

Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results from SCALE(TM) Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue for chronic weight management, were presented for the first time at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco,...

2014-06-10 08:30:52

Phase 3 Study Results Across Different Patient Populations, Including Comparative Analyses with Sitagliptin and Health Economics Data, are Among 15 Accepted Presentations RARITAN, N.J., June 10, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that 15 presentations on INVOKANA(®) (canagliflozin) will be made at the American Diabetes Association (ADA) 74(th) Scientific Sessions(®), June 13-17 in San Francisco. The presentations include long-term safety...

2014-05-27 12:27:43

Traditional Type 2 Diabetes Drug Attributes Continue to be Key Even as First-Line Treatment Paradigms Shift, According to Findings from Decision Resources Group BURLINGTON, Mass., May 27, 2014 /PRNewswire/ -- Decision Resources Group finds that Eli Lilly's insulin peglispro is set to become the clinical gold-standard in the treatment of patients with type 2 diabetes inadequately controlled with diet and exercise, when metformin is not a therapeutic option. Although metformin continues to...

2014-05-26 08:22:34

INVOKANA((TM) )offers a new approach to treatment TORONTO, May 26, 2014 /CNW/ - Janssen Inc. announced today that Health Canada has approved INVOKANA((TM) )(canagliflozin), an oral, once-daily prescription treatment used to lower blood glucose (sugar) levels in adults with type 2 diabetes.(1) INVOKANA((TM) )belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors that offers a novel approach to treating diabetes by increasing the loss of...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related